News | November 13, 2014

SPECT-Guided Treatment Improves Outcomes in Psychiatric Patients

SPECT imaging, Vancouver, psychiatry, mental health

Nov. 13, 2014 — A new study by clinicians and researchers from Toronto and Vancouver, Canada, found that psychiatric patients who underwent SPECT-influenced treatments improved significantly more than patients who did not.

Published in the Journal of Neuropsychiatry, the study used SPECT imaging – Single Photon Emission Computed Tomography that measures blood flow and shows over-activity, under-activity or non-activity in the brain. The research shows that SPECT imaging is a potentially helpful tool to gain more information on patients who struggle with mental health issues and thus better target their treatment.

Daniel Amen, M.D., Founder of Amen Clinics who is not related to the research says, "This study points to a significant advancement in the care of people who suffer with mental health issues. Until now, standard diagnoses in psychiatry are made primarily through talking to patients and looking at symptom clusters without any biological information. Psychiatry is the only medical specialty that virtually never looks at the organ it treats. It is a major step forward."

Researchers and clinicians have debated the clinical benefits of SPECT for decades, but ongoing new research consistently is showing its value in clinical practice.

The clinicians involved in the study have been using SPECT in clinical practice for nearly a decade and have recruited other physicians in Canada to do the same. There are a number of clinics in the United States, Japan and Chili who use SPECT on a regular basis.

Results from Toronto and Vancouver, Canada study not only support SPECT imaging science in treating patients for improved outcomes, but also aids the debate – supporting that SPECT is a groundbreaking tool that should be used in treatment of mental healthf.

For more information:

Related Content

PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
Vital Unveils Newest Vitrea Advanced Visualization Release at RSNA 2017
Technology | Advanced Visualization | December 04, 2017
Vital Images unveiled the newest version of Vitrea Advanced Visualization software, the cornerstone of its imaging...
Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease
News | Radiopharmaceuticals and Tracers | October 27, 2017
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a funding partnership to...
Netherlands Cancer Institute Exploring Molecular Imaging Technology for Prostate Cancer Surgery
News | Molecular Imaging | October 26, 2017
The Netherlands Cancer Institute (NKI) announced it has received funding from the Dutch Cancer Society (KWF...
SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Biodex Unveils Atomlab 500 Dose Calibrator and Wipe Test Counter
Technology | Nuclear Imaging | October 19, 2017
Biodex Medical Systems announced the full release of the Atomlab Dose Calibrator and Wipe Test Counter to the market...
ASNC and ASE Team Up to Expand ImageGuide Registry
News | Cardiovascular Ultrasound | October 12, 2017
The American Society of Nuclear Cardiology (ASNC) and the American Society of Echocardiography (ASE) jointly announced...
MR Solutions Showcases Multimodality MRI Solutions on Two Continents
News | Magnetic Resonance Imaging (MRI) | October 11, 2017
October 11, 2017 — MR Solutions took their cryogen-free preclinical multimodality...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
News | Business | September 19, 2017
September 19, 2017 — Invicro LLC, a provider of imaging services and software for research and drug development, anno
Overlay Init